We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. PCI improved angina symptoms at 12 weeks vs. a sham ...

In 2018, Medicare established coverage and reimbursement for its first service using artificial intelligence (AI): computed tomography (CT) fractional flow reserve (FFRCT). FFRCT is used in ...

Invasive coronary functional testing to identify the cause of angina in patients with nonobstructive coronary artery disease (ANOCA) can be performed safely at both experienced and less-experienced ...

ATLANTA -- For people with stable coronary artery disease and refractory angina, a coronary sinus reducer (CSR) implant showed a symptom alleviation benefit in the small placebo-controlled ...

NEW ORLEANS — An evaluation of myocardial blood flow with stress perfusion cardiac magnetic resonance (CMR) imaging after a negative angiogram changed the presumed diagnosis and treatment in the ...

ATLANTA, GA—An implantable coronary sinus reducer (CSR) in patients with refractory angina significantly reduces symptoms over 6 months of follow-up compared with a placebo procedure, a new study ...

PARIS — After the first major prospective study to associate percutaneous intervention (PCI) with symptom relief in stable angina captured international attention, a new analysis of the ...

Please provide your email address to receive an email when new articles are posted on . Quality of life and angina burden were similar after CT or invasive angiography for CAD diagnosis. Women ...

Women with severe coronary heart disease causing narrowing or blockages in the arteries may derive greater long-term benefits from coronary artery bypass grafting compared with percutaneous coronary ...

Ischemic heart disease is the leading cause of disability and premature death worldwide. Chronic coronary syndrome (CCS), previously known as stable angina, is a progressive and chronic disease of the ...

We're excited to support a new $55m global research programme called VISIBLE from Wellcome Leap - jointly funded by Pivotal - ...